BB Biotech Overview

  • Founded
  • 1993

Founded
  • Status
  • Public

  • Stock Symbol
  • BBZA

Stock Symbol
  • Investments
  • 77

  • Share Price
  • $57.34

  • (As of Monday Closing)

BB Biotech General Information

Description

BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market and is one of the largest investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. BB Biotech follows a strategy of carefully screening and selecting biotechnology firms with a long-term time horizon and having established products in the marketplace. Geographically it earns key revenue from the Netherlands.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Other Capital Markets/Institutions
Stock Exchange
FRA
Primary Office
  • Schwertstrasse 6
  • 8200 Schaffhausen
  • Switzerland
+41 052 000 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BB Biotech Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$57.34 $57.42 $51.10 - $73.64 $3.13B 54.8M 2.8K -$6.81

BB Biotech Financials Summary

In Thousands,
USD
TTM 31-Dec-2022 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 3,627,667 3,627,667 4,740,065 4,824,966
Revenue (327,811) (327,811) (376,874) 787,986
Net Income (374,739) (374,739) (442,781) 736,067
Total Assets 3,293,342 3,293,342 3,986,524 4,536,140
Total Debt 391,527 391,527 388,360 72,109
Public Fundamental Data provided by Morningstar, Inc. disclaimer

BB Biotech Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore BB Biotech‘s full profile, request access.

Request a free trial

BB Biotech Executive Team (19)

Name Title Board Seat Contact Info
Maria-Grazia Iten-Alderuccio Director, Investor Relations
Claude Mikkelsen Director of Investor Relations
Silvia Schanz Ph.D Director of Investor Relations
Daniel Koller Ph.D Head Investment Management Team
Leonidas Georgiou Portfolio Manager
You’re viewing 5 of 19 executive team members. Get the full list »

BB Biotech Board Members (8)

Name Representing Role Since
00000 00000000 00. The Medicines Company Vice Chairman 000 0000
00000 00000000 00. Self Chairman of the Board 000 0000
0000 0000000 00.0 Self Board Member 000 0000
000000 000 000000 BB Biotech Board Member 000 0000
You’re viewing 4 of 8 board members. Get the full list »

BB Biotech Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore BB Biotech‘s full profile, request access.

Request a free trial

BB Biotech Investments & Acquisitions (77)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 0000000 22-Sep-2022 00000 0000 00000 Drug Discovery
00000 0000000 22-Apr-2021 0000 Drug Discovery
00000 0000 00 12-Feb-2021 0000 Drug Discovery
00000000000 12-Feb-2021 0000 Drug Discovery
Argenx 05-Feb-2021 PIPE 00.000 Biotechnology
You’re viewing 5 of 77 investments and acquisitions. Get the full list »

BB Biotech ESG

Risk Overview

Risk Rating

Updated October, 27, 2022

23.72 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,231

Rank

00.00

Percentile

Diversified Financials

Industry

00 of 867

Rank

00.00

Percentile

Asset Management and Custody Services

Subindustry

00 of 389

Rank

00.00

Percentile

To view BB Biotech’s complete esg history, request access »

BB Biotech Exits (43)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000000 0000000000 01-Jan-2020 0000 Completed
  • 00 0000000
0000 000000 01-Jan-2019 0000 000 Completed
  • 2 buyers
000000 00000000000 08-Aug-2018 0000 00.000 Completed
  • 2 buyers
0000000 0000000000 01-Feb-2018 00000 00000 00 00000 Completed
  • 16 buyers
Radius Health 05-Jun-2017 PIPE Completed
  • 2 buyers
You’re viewing 5 of 43 exits. Get the full list »